Stockreport

ProKidney drops Phase III CKD study to focus on US market and save up to $175m [Yahoo! Finance]

ProKidney Corp. - Class A Ordinary Shares  (PROK) 
PDF The US-based biotech's Phase III program consisted of two studies; the REGEN-006 (PROACT 1) (NCT05099770) study in the US and the REGEN-016 (PROACT 2) (NCT05286853) stu [Read more]